CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes

Circulation Research

Volumn 105, Issue 4, 2009, Pages 316-325

  MacDonnell, Scott M ^a   Weisser Thomas, Jutta ^a   Kubo, Hajime ^a   Hanscome, Marie ^a   Liu, Qinghang ^b   Jaleel, Naser ^a   Berretta, Remus ^a   Chen, Xiongwen ^a   Brown, Joan H ^c   Sabri, Abdel Karim ^a   Molkentin, Jeffery D ^b   Houser, Steven R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcineurin; CaMKII; Heart disease; Myocytes; NFAT

Indexed keywords

CALCINEURIN; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASPASE 3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT3; TRANSCRIPTION FACTOR NFATC3; UNCLASSIFIED DRUG; CALMODULIN; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, RAT; MUSCLE PROTEIN; NFATC3 PROTEIN, HUMAN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; ENZYME ACTIVITY; GENE TRANSFER; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE FIBER CULTURE; NEWBORN; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ACTIVE TRANSPORT; ANIMAL; CARDIOMEGALY; CAT; CELL NUCLEUS; CELL STRAIN K 562; CYTOPLASM; GENETICS; HEART VENTRICLE; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CALCINEURIN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALMODULIN; CARDIOMEGALY; CASPASE 3; CATS; CELL NUCLEUS; CYTOPLASM; HEART VENTRICLES; HUMANS; K562 CELLS; MUSCLE PROTEINS; MUTATION; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70349236112     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.194035     Document Type: Article

References (51)

1. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205.
2. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev. 2006;7:589-600.
3. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228. (Pubitemid 28180855)
4. Maier LS, Bers DM. Calcium, calmodulin, and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. J Mol Cell Cardiol. 2002; 34:919-939.
5. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87:731-738.
6. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y, Komuro I. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001;104:97-101. (Pubitemid 32623296)
7. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
8. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;322: 1178-1191.
9. Dong D, Duan Y, Guo J, Roach DE, Swirp SL, Wang L, Lees-Miller JP, Sheldon RS, Molkentin JD, Duff HJ. Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels. Cardiovasc Res. 2003;57:320-332.
10. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101: 2863-2869.
11. Diedrichs H, Chi M, Boelck B, Mehlhorn U, Schwinger RH. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure [published erratum appears in Eur J Heart Fail. 2004;6:823]. Eur J Heart Fail. 2004;6:3-9.
12. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW, II, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosisindependent model of dilated heart failure. Circ Res. 2000;86:255-263.
13. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res. 2003;92:725-731.
14. Semeniuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD, Duff HJ. Time-dependent systolic and diastolic function in mice overexpressing calcineurin. Am J Physiol Heart Circ Physiol. 2003;284: H425-H430.
15. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92: 912-919.
16. Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter CE, Guan X, Oddis CV, Zhang R, Mendes L, Ni G, Madu EC, Yang J, Bass M, Gomez RJ, Wadzinski BE, Olson EN, Colbran RJ, Anderson ME. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation. 2006;114: 1352-1359.
17. 2+/calmodulin kinase II. J Clin Invest. 2003;111:617-625.
18. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res. 2004;63: 476-486.
19. Erickson JR, Anderson ME. CaMKII and its role in cardiac arrhythmia. J Cardiovasc Electrophysiol. 2008;19:1332-1336.
20. 2+/calmodulin-dependent protein kinase isoforms. Biochim Biophys Acta. 1994;1221:89-101.
21. Mayer P, Mohlig M, Idlibe D, Pfeiffer A. Novel and uncommon isoforms of the calcium sensing enzyme calcium/calmodulin dependent protein kinase II in heart tissue. Basic Res Cardiol. 1995;90:372-379.
22. 2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem. 1997;272:31203-31208.
23. Zhang T, Kohlhaas M, Backs J, Mishra S, Phillips W, Dybkova N, Chang S, Ling H, Bers DM, Maier LS, Olson EN, Brown JH. CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem. 2007;282: 35078-35087.
24. 2+/ calmodulindependent protein kinase in failing and nonfailing human myocardium. Circ Res. 1999;84:713-721.
25. 2+/calmodulin- dependent kinase II in the transition from pressure overloadinduced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119:1230-1240.
26. 2+ current in rabbit ventricular myocytes. Circ Res. 1994;75:854-861.
27. Zhu W, Woo AY, Yang D, Cheng H, Crow MT, Xiao RP. Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuliinduced heart muscle cell apoptosis. J Biol Chem. 2007;282: 10833-10839.
28. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005;11:409-417.
29. Hama N, Paliogianni F, Fessler BJ, Boumpas DT. Calcium/ calmodulindependent protein kinase II downregulates both calcineurin and protein kinase C-mediated pathways for cytokine gene transcription in human T cells. J Exp Med. 1995;181:1217-1222.
30. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, Bassel-Duby R, Williams RS. A calcineurin-dependen transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12:2499-2509.
31. Gaughan JP, Hefner CA, Houser SR. Electrophysiological properties of neonatal rat ventricular myocytes with alpha1-adrenergic-induced hypertrophy. Am J Physiol. 1998;275:H577-H590.
32. Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res. 1982;51:787-801.
33. Bailey BA, Houser SR. Sarcoplasmic reticulum-related changes in cytosolic calcium in pressure-overload-induced feline LV hypertrophy. Am J Physiol. 1993;265:H2009-H2016.
34. 2+ release. Circ Res. 2005;96:543-550.
35. MacDonnell SM, Kubo H, Crabbe DL, Renna BF, Reger PO, Mohara J, Smithwick LA, Koch WJ, Houser SR, Libonati JR. Improved myocardial beta-adrenergic responsiveness and signaling with exercise training in hypertension. Circulation. 2005;111:3420-3428.
36. Bailey BA, Houser SR. Calcium transients in feline left ventricular myocytes with hypertrophy induced by slow progressive pressure overload. J Mol Cell Cardiol. 1992;24:365-373.
37. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002; 99:907-912.
38. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103:670-677.
39. Liu Q, Wilkins BJ, Lee YJ, Ichijo H, Molkentin JD. Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol. 2006;26:3785-3797.
40. 2+/calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A. 1988;85:7001-7005.
41. 2+/ calmodulin-dependent protein kinase II and protein kinase C. J Biol Chem. 1989;264:16524-16529.
42. 2+/CaM-dependent kinase II: modification of the CaM-binding domain. Biochemistry. 1989;28:9243-9247.
43. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. 2nd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2001.
44. 2+ in resting feline and rat ventricular myocytes. Cell Calcium. 1987;8:259-268.
45. Houser SR, Piacentino V III, Mattiello J, Weisser J, Gaughan JP. Functional properties of failing human ventricular myocytes. Trends Cardiovasc Med. 2000;10:101-107.
46. Molkentin JD, Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426.
47. Goto S, Yamamoto H, Fukunaga K, Iwasa T, Matsukado Y, Miyamoto E. Dephosphorylation of microtubule-associated protein 2, tau factor, and tubulin by calcineurin. J Neurochem. 1985;45:276-283.
48. El-Armouche A, Bednorz A, Pamminger T, Ditz D, Didie M, Dobrev D, Eschenhagen T. Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun. 2006;346:700-706.
49. Atkins FL, Bing OH, DiMauro PG, Conrad CH, Robinson KG, Brooks WW. Modulation of left and right ventricular beta-adrenergic receptors from spontaneously hypertensive rats with left ventricular hypertrophy and failure. Hypertension. 1995;26:78-82.
50. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of betaadrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem. 1997;272:17223-17229.
51. Yang Y, Zhu WZ, Joiner ML, Zhang R, Oddis CV, Hou Y, Yang J, Price EE, Gleaves L, Eren M, Ni G, Vaughan DE, Xiao RP, Anderson ME. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol. 2006;291:H3065-H3075